OncoMatch/Clinical Trials/NCT06359275
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Is NCT06359275 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PD-1 and Nab-paclitaxel for pancreatic cancer.
Treatment: PD-1 · Nab-paclitaxel · Gemcitabine — This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients with only local recurrence after pancreatic cancer surgery, to observe the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR in the treatment of patients with locally advanced unresectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage III
Excluded: Stage DISTANT METASTASIS
locally advanced pancreatic adenocarcinoma ... or pancreatic cancer with only local recurrence but no distant metastasis after surgery
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Have received anti-PD-1 or anti-PD-L1 antibody treatment in the past
Cannot have received: anti-PD-L1 therapy
Have received anti-PD-1 or anti-PD-L1 antibody treatment in the past
Cannot have received: systemic therapy for locally advanced pancreatic cancer
Previous systemic treatment for locally advanced pancreatic cancer
Cannot have received: radiotherapy (upper abdomen)
Have received radiotherapy for the upper abdomen in the past
Cannot have received: investigational drug
Have received any investigational drugs within 4 weeks before using the investigational drugs for the first time
Cannot have received: experimental drug
Have received any experimental drug treatment or participated in another interventional clinical trial within 30 days of the screening period
Cannot have received: taxane-containing regimen (neoadjuvant/adjuvant)
Exception: only if pathologically diagnosed with squamous cell carcinoma (not limited to organs)
Subjects who have been pathologically diagnosed with squamous cell carcinoma (not limited to organs) and received taxane-containing regimens as neoadjuvant/adjuvant treatment
Lab requirements
Blood counts
ANC ≥1.5×10^9/L; PLT ≥80×10^9/L; Hb ≥90g/L
Kidney function
serum creatinine ≤ 1.5x ULN, or calculated creatinine clearance ≥ 50ml/min
Liver function
Total bilirubin (TBil) ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN (≤5x ULN if liver metastasis present)
Hematological dysfunction is defined as i) absolute neutrophil (ANC) count ≥1.5×109/L; ii) platelet (PLT) count: ≥80×109/L; iii) hemoglobin (Hb) level ≥ 90g/L. Abnormal liver function is defined as: i) Total bilirubin (TBil) level: ≤ 1.5 times the upper limit of normal (ULN); ii) Aspartate aminotransferase (AST) and alanine; aminotransferase (ALT) levels ≤ 2.5 times the ULN, if liver metastasis is present, ≤5 times ULN; Abnormal renal function definition: serum creatinine ≤ 1.5 times ULN, or calculated creatinine clearance ≥ 50ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify